Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ...
Announcing a new article publication for Zoonoses journal. The prevalence of antimicrobial resistance is increasing among gram-positive bacteria, particularly the resistance of methicillin-resistant ...
In a recent study, researchers demonstrated that a novel compound could treat flesh-eating Gram-positive bacterial infections in mice, potentially offering a new class of antibiotics. Researchers at ...
Animal tests show promise to target invasive strain of E. coli but approval for use in humans is still years away ...
Researchers at Washington University School of Medicine in St. Louis developed a novel compound that effectively clears Gram-positive bacterial infections in mice, in particular skin and soft tissue ...
Half of the Staphylococcus epidermidis isolates found in raw milk from dairy cattle and sheep were multidrug resistant.
Symptoms and Patient-Reported Well-Being: Do They Predict Survival in Malignant Pleural Mesothelioma? A Prognostic Factor Analysis of EORTC-NCIC 08983: Randomized Phase III Study of Cisplatin With or ...
Due to increasing antibiotic resistance in pathogens causing infections, the development of new antibacterial substances is needed. Scientists are testing out a new group of substances produced by ...
BEVs carry diverse molecular cargo that offers non-invasive biomarkers for early diagnosis and monitoring of PCOS and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback